AGR2

Across TCGA pan-cancer cohorts, AGR2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated AGR2 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher AGR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGR2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

THCA, LUAD, and COAD are the cancer types where AGR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.098	0.941	<.001	42	view →
LUAD	OS	Median	All	0.156	0.812	<.001	24	view →
COAD	OS	Median	All	0.168	0.806	.002	24	view →
LIHC	OS	Median	All	0.127	0.786	<.001	15	view →
SARC	OS	Median	All	0.022	0.861	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	III,IV	1.000	0.346	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

AGR2–THCA (OS)

Open the THCA breakdown →